BioCryst Pharmaceuticals, Inc. (BCRX)
8.68
-0.02
(-0.23%)
USD |
NASDAQ |
Sep 18, 16:00
8.61
-0.07
(-0.81%)
After-Hours: 20:00
BioCryst Pharmaceuticals 30-Day Average Daily Volume : 4.142M for Sept. 18, 2026
30-Day Average Daily Volume Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical 30-Day Average Daily Volume Data
| Date | Value |
|---|---|
| September 18, 2026 | 4.142M |
| September 17, 2026 | 3.852M |
| September 16, 2026 | 3.881M |
| September 15, 2026 | 3.783M |
| September 14, 2026 | 3.686M |
| September 11, 2026 | 3.613M |
| September 10, 2026 | 3.571M |
| September 09, 2026 | 3.344M |
| September 08, 2026 | 3.268M |
| September 04, 2026 | 3.089M |
| September 03, 2026 | 3.101M |
| September 02, 2026 | 3.090M |
| September 01, 2026 | 3.070M |
| August 31, 2026 | 3.034M |
| August 28, 2026 | 3.022M |
| August 27, 2026 | 3.041M |
| August 26, 2026 | 3.077M |
| August 25, 2026 | 3.242M |
| August 24, 2026 | 3.297M |
| August 21, 2026 | 3.335M |
| August 20, 2026 | 3.363M |
| August 19, 2026 | 3.419M |
| August 18, 2026 | 3.569M |
| August 17, 2026 | 3.841M |
| August 14, 2026 | 3.916M |
| Date | Value |
|---|---|
| August 13, 2026 | 3.951M |
| August 12, 2026 | 3.961M |
| August 11, 2026 | 4.089M |
| August 10, 2026 | 4.139M |
| August 07, 2026 | 4.371M |
| August 06, 2026 | 4.861M |
| August 05, 2026 | 5.010M |
| August 04, 2026 | 4.978M |
| August 03, 2026 | 5.128M |
| July 31, 2026 | 5.317M |
| July 30, 2026 | 5.368M |
| July 29, 2026 | 5.410M |
| July 28, 2026 | 5.475M |
| July 27, 2026 | 5.459M |
| July 24, 2026 | 5.443M |
| July 23, 2026 | 5.503M |
| July 22, 2026 | 5.575M |
| July 21, 2026 | 5.626M |
| July 20, 2026 | 5.633M |
| July 17, 2026 | 5.669M |
| July 16, 2026 | 5.701M |
| July 15, 2026 | 5.733M |
| July 14, 2026 | 5.608M |
| July 13, 2026 | 5.584M |
| July 10, 2026 | 5.590M |
30-Day Average Daily Volume Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
30-Day Average Daily Volume Benchmarks
| Amgen, Inc. | 2.718M |
| Halozyme Therapeutics, Inc. | 2.301M |
| Neurocrine Biosciences, Inc. | 1.156M |
| Vertex Pharmaceuticals, Inc. | 1.092M |
| Agenus, Inc. | 1.072M |